Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Inclusion Criteria:

• Male or female aged 18-60.

• Body mass index ≥ 18 kg/m2 and ≤ 32 kg/m2.

• Chronic HBV infection for ≥ 6 months.

• On NRTI therapy for at least 6 months.

Exclusion Criteria:

• Any clinically significant chronic or acute medical condition that makes theparticipant unsuitable for participation.

• Significant liver fibrosis or cirrhosis.

• History or evidence of drug or alcohol abuse.

• History of intolerance to SC injection.

• History of chronic liver disease from any cause other than chronic HBV infection.

• History of hepatic decompensation.

• Contraindications to the use of Peg-IFNα.